{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T04:30:45Z","timestamp":1792557045068,"version":"4.5.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["8076023"],"award-info":[{"award-number":["8076023"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardio-Oncology"],"DOI":"10.1186\/s40959-025-00368-9","type":"journal-article","created":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T09:37:11Z","timestamp":1756719431000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["SGLT2i Dapagliflozin in primary prevention of chemotherapy induced cardiotoxicity in breast cancer patients treated with neo-adjuvant anthracycline-based chemotherapy +\/- trastuzumab: rationale and design of the multicenter PROTECT trial"],"prefix":"10.1186","volume":"11","author":[{"given":"A.","family":"Greco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Quagliariello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Rizzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Tedeschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Schirinzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Turco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Galiazzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Acquaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"De Amicis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Klersy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Ghio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Perrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Paccone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Uccello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. L.","family":"Canale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Oliva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Guerra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"De Luca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Maurea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Scelsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,1]]},"reference":[{"key":"368_CR1","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/978-3-030-43032-0_15","volume":"1257","author":"B Anchit","year":"2020","unstructured":"Anchit B, et al. Anthracycline-Induced cardiotoxicity: causes, mechanisms, and prevention. Adv Exp Med Biol. 2020;1257:181\u201392.","journal-title":"Adv Exp Med Biol"},{"key":"368_CR2","doi-asserted-by":"crossref","unstructured":"Cardinale D et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation. 2015;131(22):1981-8.","DOI":"10.1161\/CIRCULATIONAHA.114.013777"},{"key":"368_CR3","doi-asserted-by":"crossref","unstructured":"Role of cardiovascular imaging. In cancer patients receiving cardiotoxic therapies: a position statement on behalf of the Heart Failure Association [HFA], the European Association of Cardiovascular Imaging [EACVI] and the Cardio-Oncology Council of the European Society of Cardiology [ESC]. Eur J Heart Fail. 2020;22:1504\u201324.","DOI":"10.1002\/ejhf.1957"},{"key":"368_CR4","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/S1470-2045(17)30716-7","volume":"191","author":"SA Hurvitz","year":"2018","unstructured":"Hurvitz SA, et al. Neoadjuvant trastuzumab, Pertuzumab, and chemotherapy versus trastuzumab emtansine plus Pertuzumab in patients with HER2-positive breast cancer [KRISTINE]: a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 2018;191:115\u201326.","journal-title":"Lancet Oncol"},{"key":"368_CR5","first-page":"122","volume":"3772","author":"G Von Minckwitz","year":"2017","unstructured":"Von Minckwitz G, et al. APHINITY Steering Committee and Investigators. Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer. N Engl. J Med. 2017;3772:122\u201331.","journal-title":"J Med"},{"key":"368_CR6","doi-asserted-by":"crossref","unstructured":"Swain SM et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer [CLEOPATRA study]: overall survival results from a randomised, double-blind, placebo-controlled, III 3 study. Lancet Oncol. 2013;14(6):461\u2013\u200971.","DOI":"10.1016\/S1470-2045(13)70130-X"},{"key":"368_CR7","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1056\/NEJM200103153441101","volume":"344","author":"DJ Slamon","year":"2001","unstructured":"Slamon DJ, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783\u201392.","journal-title":"N Engl J Med"},{"key":"368_CR8","first-page":"CD006243","volume":"4","author":"L Moja","year":"2012","unstructured":"Moja L, et al. Trastuzumab containing regimens for early breast cancer. Cochrane Database Syst Rev. 2012;4:CD006243.","journal-title":"Cochrane Database Syst Rev"},{"key":"368_CR9","doi-asserted-by":"publisher","first-page":"3859","DOI":"10.1200\/JCO.2006.09.1611","volume":"25","author":"TM Suter","year":"2007","unstructured":"Suter TM, et al. Trastuzumab-associated cardiac adverse effects in the Herceptin adjuvant trial. J Clin Oncol. 2007;25:3859.\u2013\u20093865.","journal-title":"J Clin Oncol"},{"key":"368_CR10","unstructured":"Alexander R, Lyon et al. ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association [EHA], the European Society for Therapeutic Radiology and Oncology [ESTRO] and the International Cardio-Oncology Society [IC-OS]: Developed by the task force on cardio-oncology of the European Society of Cardiology [ESC]. Eur Heart J. 2022; ehac244."},{"key":"368_CR11","doi-asserted-by":"crossref","unstructured":"Ma Y et al. Beta-blockers for the primary prevention of anthracycline-induced cardiotoxicity: a meta-analysis of randomized controlled trials. BMC Pharmacol Toxicol. 2019;20(1):18.","DOI":"10.1186\/s40360-019-0298-6"},{"key":"368_CR12","first-page":"2355","volume":"6123","author":"B Xavier","year":"2013","unstructured":"Xavier B, et al. Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial [preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies]. J Am Coll Cardiol. 2013;6123:2355\u201362.","journal-title":"J Am Coll Cardiol"},{"key":"368_CR13","first-page":"1671","volume":"3721","author":"G Geeta","year":"2016","unstructured":"Geeta G, et al. Prevention of cardiac dysfunction during adjuvant breast cancer therapy [PRADA]: a 2 \u00d7 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. Eur Heart J. 2016;3721:1671\u201380.","journal-title":"Eur Heart J"},{"key":"368_CR14","unstructured":"Liang, Liu et al. Preventive effect of low-dose carvedilol combined with candesartan on the cardiotoxicity of anthracycline drugs in the adjuvant chemotherapy of breast cancer. Zhonghua Zhong Liu Za Zhi. 2013;35(12):936\u2013\u200940."},{"key":"368_CR15","doi-asserted-by":"crossref","unstructured":"Muthiah V, et al. Efficacy of neurohormonal therapies in preventing cardiotoxicity in patients with cancer undergoing chemotherapy. J Am Coll Cardiol CardioOnc. 2019 Sep;1:54\u201365.","DOI":"10.1016\/j.jaccao.2019.08.006"},{"key":"368_CR16","doi-asserted-by":"crossref","unstructured":"Zinman B et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373. 2015;2117\u201328.","DOI":"10.1056\/NEJMoa1504720"},{"key":"368_CR17","doi-asserted-by":"crossref","unstructured":"Neal B et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377. 2017;644\u201357.","DOI":"10.1056\/NEJMoa1611925"},{"key":"368_CR18","doi-asserted-by":"crossref","unstructured":"Perkovic V et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 380. 2019;2295\u2013306.","DOI":"10.1056\/NEJMoa1811744"},{"key":"368_CR19","doi-asserted-by":"crossref","unstructured":"Wiviott SD et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 380. 2019;347\u201357.","DOI":"10.1056\/NEJMoa1812389"},{"key":"368_CR20","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"Packer M, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383:1413\u201324.","journal-title":"N Engl J Med"},{"key":"368_CR21","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, et al. DAPA-HF trial committees and investigators. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381:1995\u20132008.","journal-title":"N Engl J Med"},{"key":"368_CR22","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1161\/CIRCULATIONAHA.119.042929","volume":"140","author":"ME Nassif","year":"2019","unstructured":"Nassif ME, et al. Dapagliflozin effects on biomarkers, symptoms, and functional status in patients with heart failure with reduced ejection fraction: the DEFINE-HF trial. Circulation. 2019;140:1463\u201376.","journal-title":"Circulation"},{"key":"368_CR23","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","volume":"38712","author":"SD Solomon","year":"2022","unstructured":"Solomon SD, McMurray JJV, Claggett B, de Boer RA, DeMets D, Hernandez AF, Inzucchi SE, Kosiborod MN, Lam CSP, Martinez F, Shah SJ, Desai AS, Jhund PS, Belohlavek J, Chiang CE, Borleffs CJW, Comin-Colet J, Dobreanu D, Drozdz J, Fang JC, Alcocer-Gamba MA, Al Habeeb W, Han Y, Cabrera Honorio JW, Janssens SP, Katova T, Kitakaze M, Merkely B, O\u2019Meara E, Saraiva JFK, Tereshchenko SN, Thierer J, Vaduganathan M, Vardeny O, Verma S, Pham VN, Wilder\u00e4ng U, Zaozerska N, Bachus E, Lindholm D, Petersson M, Langkilde AM. DELIVER trial committees and investigators. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022;38712:1089\u201398. https:\/\/doi.org\/10.1056\/NEJMoa2206286.","journal-title":"N Engl J Med"},{"key":"368_CR24","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.jchf.2022.03.006","volume":"108","author":"CA Gongora","year":"2022","unstructured":"Gongora CA, Drobni ZD, Quinaglia Araujo Costa Silva T, Zafar A, Gong J, Zlotoff DA, Gilman HK, Hartmann SE, Sama S, Nikolaidou S, Suero-Abreu GA, Jacobsen E, Abramson JS, Hochberg E, Barnes J, Armand P, Thavendiranathan P, Nohria A, Neilan TG. Sodium-Glucose Co-Transporter-2 inhibitors and cardiac outcomes among patients treated with anthracyclines. JACC Heart Fail. 2022;108:559\u201367. https:\/\/doi.org\/10.1016\/j.jchf.2022.03.006.","journal-title":"JACC Heart Fail"},{"key":"368_CR25","unstructured":"Theresa AMD, ESC Scientific Document Group., 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology [ESC] With the special contribution of the Heart Failure Association [HFA] of the ESC. Eur J Heart Fail. Sept 2021; 42(36):3599\u20133726."},{"key":"368_CR26","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/S2213-8587[20]30162-5","volume":"8","author":"DZI Cherney","year":"2020","unstructured":"Cherney DZI, et al. Effects of the SGLT2 inhibitor Dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease [DIAMOND]: a randomised, double\u2010blind, crossover trial. Lancet Diabetes Endocrinol. 2020;8:582\u201393. https:\/\/doi.org\/10.1016\/S2213-8587[20]30162-5.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"368_CR27","doi-asserted-by":"crossref","unstructured":"Sherif F, Nagueh et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American society of echocardiography and the European association of cardiovascular imaging. Eur Heart J\u2013 Cardiovasc Imaging. 2016;17:1321\u201360.","DOI":"10.1093\/ehjci\/jew041"},{"issue":"1","key":"368_CR28","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1002\/ejhf.654","volume":"19","author":"JL Zamorano","year":"2017","unstructured":"Zamorano JL, Lancellotti P, Rodriguez Munoz D, Aboyans V, Asteggiano R, Galderisi M, et al. 2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC committee for practice guidelines: the task force for cancer treatments and cardiovascular toxicity of the European society of cardiology (ESC). Eur J Heart Fail. 2017;19(1):9\u201342.","journal-title":"Eur J Heart Fail"},{"key":"368_CR29","doi-asserted-by":"publisher","unstructured":"Volkova M, Russell R 3. Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment. Curr Cardiol Rev. 2011;7(4):214\u201320. https:\/\/doi.org\/10.2174\/157340311799960645. PMID: 22758622; PMCID: PMC3322439.","DOI":"10.2174\/157340311799960645"},{"issue":"1","key":"368_CR30","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/s00520-024-09067-0","volume":"33","author":"J Kuroda","year":"2024","unstructured":"Kuroda J, Oikawa M, Tokuda E, Tachibana K, Sasaki E, Ohtake T, Takeishi Y, Saji S. Development of cancer therapy-related cardiac dysfunction in anthracycline-treated breast cancer patients: a retrospective study. Support Care Cancer. 2024;33(1):8. https:\/\/doi.org\/10.1007\/s00520-024-09067-0. PMID: 39648236; PMCID: PMC11625689.","journal-title":"Support Care Cancer"},{"issue":"23","key":"368_CR31","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1161\/CIRCULATIONAHA.106.635144","volume":"114","author":"D Cardinale","year":"2006","unstructured":"Cardinale D, Colombo A, Sandri MT, Lamantia G, Colombo N, Civelli M, et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme Inhibition. Circulation. 2006;114(23):2474\u201381.","journal-title":"Circulation"},{"issue":"3","key":"368_CR32","doi-asserted-by":"publisher","first-page":"e4871","DOI":"10.1016\/j.ahj.2010.05.037","volume":"160","author":"C Cadeddu","year":"2010","unstructured":"Cadeddu C, Piras A, Mantovani G, Deidda M, Dessi M, Madeddu C, et al. Protective effects of the angiotensin II receptor blocker Telmisartan on epirubicin-induced inflammation, oxidative stress, and early ventricular impairment. Am Heart J. 2010;160(3):e4871\u20137.","journal-title":"Am Heart J"},{"issue":"9","key":"368_CR33","doi-asserted-by":"publisher","first-page":"2320","DOI":"10.3390\/cancers14092320","volume":"14","author":"SH Lee","year":"2022","unstructured":"Lee SH, Cho I, You SC, Cha MJ, Chang JS, Kim WD, Go KY, Kim DY, Seo J, Shim CY, Hong GR, Kang SM, Ha JW, Rha SY, Kim HS. Cancer Therapy-Related cardiac dysfunction in patients treated with a combination of an immune checkpoint inhibitor and doxorubicin. Cancers (Basel). 2022;14(9):2320. https:\/\/doi.org\/10.3390\/cancers14092320. PMID: 35565449; PMCID: PMC9100163.","journal-title":"Cancers (Basel)"},{"issue":"12","key":"368_CR34","doi-asserted-by":"publisher","first-page":"2914","DOI":"10.3390\/biomedicines12122914","volume":"12","author":"P Theofilis","year":"2024","unstructured":"Theofilis P, Vlachakis PK, Oikonomou E, Drakopoulou M, Karakasis P, Apostolos A, Pamporis K, Tsioufis K, Tousoulis D. Cancer Therapy-Related cardiac dysfunction: A review of current trends in epidemiology, diagnosis, and treatment. Biomedicines. 2024;12(12):2914. https:\/\/doi.org\/10.3390\/biomedicines12122914. PMID: 39767820; PMCID: PMC11673750.","journal-title":"Biomedicines"},{"issue":"1","key":"368_CR35","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s11897-025-00697-x","volume":"22","author":"E Haj-Yehia","year":"2025","unstructured":"Haj-Yehia E, Michel L, Mincu RI, Rassaf T, Totzeck M. Prevention of cancer-therapy related cardiac dysfunction. Curr Heart Fail Rep. 2025;22(1):9. https:\/\/doi.org\/10.1007\/s11897-025-00697-x. PMID: 39969700; PMCID: PMC11839799.","journal-title":"Curr Heart Fail Rep"},{"issue":"10","key":"368_CR36","doi-asserted-by":"publisher","first-page":"4780","DOI":"10.3390\/ijms26104780","volume":"26","author":"A Greco","year":"2025","unstructured":"Greco A, Canale ML, Quagliariello V, Oliva S, Tedeschi A, Inno A, De Biasio M, Bisceglia I, Tarantini L, Maurea N, Navazio A, Corda M, Iacovoni A, Colivicchi F, Grimaldi M, Oliva F. SGLT2 inhibitors in Cancer patients: A comprehensive review of clinical, biochemical, and therapeutic implications in Cardio-Oncology. Int J Mol Sci. 2025;26(10):4780. https:\/\/doi.org\/10.3390\/ijms26104780. PMID: 40429921; PMCID: PMC12112039.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"368_CR37","doi-asserted-by":"publisher","first-page":"612","DOI":"10.3390\/antiox14050612","volume":"14","author":"V Quagliariello","year":"2025","unstructured":"Quagliariello V, Di Mauro A, Ferrara G, Bruzzese F, Palma G, Luciano A, Canale ML, Bisceglia I, Iovine M, Cadeddu Dessalvi C, Maurea C, Barbato M, Inno A, Berretta M, Paccone A, Mauriello A, Fonderico C, Maratea AC, Maurea N. Cardio-Renal and systemic effects of SGLT2i Dapagliflozin on Short-Term anthracycline and HER-2-Blocking agent Therapy-Induced cardiotoxicity. Antioxid (Basel). 2025;14(5):612. https:\/\/doi.org\/10.3390\/antiox14050612. PMID: 40427493; PMCID: PMC12108597.","journal-title":"Antioxid (Basel)"},{"issue":"4","key":"368_CR38","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1111\/dom.13923","volume":"22","author":"RA Scholtes","year":"2020","unstructured":"Scholtes RA, van Raalte DH, Correa-Rotter R, Toto RD, Heerspink HJL, Cain V, Sj\u00f6str\u00f6m CD, Sartipy P, Stef\u00e1nsson BV. The effects of Dapagliflozin on cardio-renal risk factors in patients with type 2 diabetes with or without renin-angiotensin system inhibitor treatment: a post hoc analysis. Diabetes Obes Metab. 2020;22(4):549\u201356. https:\/\/doi.org\/10.1111\/dom.13923. Epub 2019 Dec 14. PMID: 31742881; PMCID: PMC7078964.","journal-title":"Diabetes Obes Metab"},{"issue":"11","key":"368_CR39","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1016\/j.jchf.2023.05.015","volume":"11","author":"JW Ostrominski","year":"2023","unstructured":"Ostrominski JW, Thierer J, Claggett BL, Miao ZM, Desai AS, Jhund PS, Kosiborod MN, Lam CSP, Inzucchi SE, Martinez FA, de Boer RA, Hernandez AF, Shah SJ, Petersson M, Langkilde AM, McMurray JJV, Solomon SD, Vaduganathan M. Cardio-Renal-Metabolic overlap, outcomes, and Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. JACC Heart Fail. 2023;11(11):1491\u2013503. https:\/\/doi.org\/10.1016\/j.jchf.2023.05.015. Epub 2023 May 24. PMID: 37226448.","journal-title":"JACC Heart Fail"},{"issue":"8","key":"368_CR40","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.jchf.2022.03.006","volume":"10","author":"CA Gongora","year":"2022","unstructured":"Gongora CA, Drobni ZD, Quinaglia Araujo Costa Silva T, Zafar A, Gong J, Zlotoff DA, Gilman HK, Hartmann SE, Sama S, Nikolaidou S, Suero-Abreu GA, Jacobsen E, Abramson JS, Hochberg E, Barnes J, Armand P, Thavendiranathan P, Nohria A, Neilan TG. Sodium-Glucose Co-Transporter-2 inhibitors and cardiac outcomes among patients treated with anthracyclines. JACC Heart Fail. 2022;10(8):559\u201367. Epub 2022 Jun 8. PMID: 35902159; PMCID: PMC9638993.","journal-title":"JACC Heart Fail"}],"container-title":["Cardio-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40959-025-00368-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40959-025-00368-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40959-025-00368-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T01:07:07Z","timestamp":1757466427000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiooncologyjournal.biomedcentral.com\/articles\/10.1186\/s40959-025-00368-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,1]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["368"],"URL":"https:\/\/doi.org\/10.1186\/s40959-025-00368-9","relation":{},"ISSN":["2057-3804"],"issn-type":[{"value":"2057-3804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,1]]},"assertion":[{"value":"6 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Ethics Committee of Fondazione IRCCS Policlinico San Matteo has approved the study and its consent to participate [number 0008491\/23]. The study will be conducted in accordance with the Declaration of Helsinki. All researchers are trained and certified in Good Clinical Practices. A written informed consent will be taken from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"79"}}